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Abstract
A consistent debate is ongoing on genome-wide association studies (GWAs). A key point is the capability to identify low-
penetrance variations across the human genome. Among the phenomena reducing the power of these analyses,
phenocopy level (PE) hampers very seriously the investigation of complex diseases, as well known in neurological disorders,
cancer, and likely of primary importance in human ageing. PE seems to be the norm, rather than the exception, especially
when considering the role of epigenetics and environmental factors towards phenotype. Despite some attempts, no
recognized solution has been proposed, particularly to estimate the effects of phenocopies on the study planning or its
analysis design. We present a simulation, where we attempt to define more precisely how phenocopy impacts on different
analytical methods under different scenarios. With our approach the critical role of phenocopy emerges, and the more the
PE level increases the more the initial difficulty in detecting gene-gene interactions is amplified. In particular, our results
show that strong main effects are not hampered by the presence of an increasing amount of phenocopy in the study
sample, despite progressively reducing the significance of the association, if the study is sufficiently powered. On the
opposite, when purely epistatic effects are simulated, the capability of identifying the association depends on several
parameters, such as the strength of the interaction between the polymorphic variants, the penetrance of the polymorphism
and the alleles (minor or major) which produce the combined effect and their frequency in the population. We conclude
that the neglect of the possible presence of phenocopies in complex traits heavily affects the analysis of their genetic data.
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Introduction
Highthroughput genetic analysis represents the present and the
future in catching the genetic determinants of complex diseas-
es[1,2,3,4,5,6]. A consistent debate is ongoing on the best approaches
to overcome the major issues inherent to genome-wide association
(GWA) study designs[7,8,9,10,11,12,13,14,15,16,17,18].
The most widely used statistical tests are single point statistics
(chi-square, or Cochrane-Armitage test) along the genome; these
tests can be integrated with haplotype (or multi-marker) analysis
once the linkage disequilibrium (LD) structure is drawn and thus
haplotype blocks have been identified.
All these tests can be performed under different assumptions
and with slightly different approaches, and multivariate analyses
are generally performed.
Two main obstacles can be envisaged as:
N the false positive rates, and consequently the efficacy of the
corrections adopted;
N the capability to identify low-penetrance variations across the
human genome.
As for false positives, many different approaches have been
proposed and, provided the sample collection to be large enough,
a multi-stage design has been shown to be very effective in
detecting key leads in the genome, often replicated in other
populations. It’s not the purpose of this paper to address this
area[7,19].
As for the identification of low-penetrance polymorphisms, the
area is of a major consideration when disentangling the picture of
any complex trait. Indeed, it’s quite realistic for complex
phenotypes to be determined by a combination of many different
polymorphic loci each of them accounting for a minor part of the
total variance[20], hence very difficult to be detected when a
genome-wide genotyping is performed and when GWA signifi-
cance rates are applied[20].
Despite this issue being of a key importance, most of the papers
reporting GWA studies applied single point statistics, multi-marker
analysis and haplotypes analyses, performed LD mapping,
adopted different false-positive rate corrections[21,22,23,24,25].
Few of them actually included interaction analysis and other
similar approaches capable to grasp the effect of interactions and
across-genome combinations, rather then the main effect of single
markers or (despite more importantly) the major contribution of a
specific haplotype in a locus[26,27,28].
Among the phenomena reducing the power of these analysis,
phenocopy hampers very seriously the investigation of complex
diseases, a well known issue in neurological disorders [29,30],
cancer [31], and likely of primary importance in the study of
human ageing [32]. However, the concept of phenocopy is quite
1)
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PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11876
old in genetics, and assumed different meanings according to
many different authors: for the purpose of this paper, we mainly
refer a definition adopted in linkage studies, where ‘‘phenocopy’’
indicates affected individuals who had acquired the disease by
different means than the ones segregating in rest of the
family[33]. Moreover, the term here needs to be even more
focused, due to the characteristics of the simulating algorithm
adopted in this study to generate the disease model and
subsequently the datasets: globally we consider here a ‘‘pheno-
copy’’ an individual marked as affected, but where the underlying
genetic markers associated with the disease are different from the
other cases in the dataset. We also aknowledge that the classical
definition of phenocopy assumes a smooth and wider perspective
when we consider the most important complex traits: in this
scenario its importance appears to be even higher, due to its
intrinsic presence when the interplay of multiple genetic loci
determines a disease. Phenocopy (indicated as PE, ‘‘phenocopy
error’’, from the terminology of the genomeSIMLA software)
seems to be the norm, rather than the exception, especially when
considering the role that epigenetics and environmental factors
exert on the phenotype [34].
Considering the scenario we are dealing with, additional
terminology needs to be clarified. As previously mentioned, one
of the hot topics geneticists are currently debating is whether the so
called ‘‘missing heritability’’ issue would find an answer in very
rare and highly penetrant mutations (detectable with exome
sequencing or whole genome next generation sequencing only
[35]), or in a multitude of polymorphisms with no effect when
considered alone (main effect) but with a more significant effect
when their statistical interaction is considered [36,37].
As far as this latter point is concerned, several models have been
proposed since many years [38] which define ‘‘epistasis’’ (again
another term used with different meanings in genetics) as the
interaction between different loci, and call ‘‘purely epistatic’’ those
interactions between loci that do not display any single locus main
effect [37,38,39]. This model has been proposed and largely
debated [34,40,41]: some authors consider the additive model
widely used as sufficient to incorporate these effects[42], or argue
about the scarce impact of such a scenario, but few papers address
specifically this topic[43,44].
Despite some attempt [45,46,47], no widely recognized solution
has been therefore proposed, particularly to estimate the effects
that phenocopies could exert either on the study planning or its
analysis design. At present, the most of the analysis strategies do
not take into account the intrinsic presence of phenocopy in
complex traits.
We present a simulation [48,49,50,51], where we attempt to
define more precisely how phenocopy impacts on different
analytical methods under different scenarios.
Results
Simulation of the datasets
Two disease models have been simulated.
In the first model, i.e ‘‘model ME’’, standing for ‘‘Main Effect’’,
the marker RL0-855 was simulated, having a main effect and an
OR=2.225. Three additional SNPs (Table 1) have been simulated
with a very small marginal effect, and an interaction associated
with the disease, according to the mixed model offered by the
logistic function of genomeSIMLA.
In the second model, i.e. ‘‘model EPI’’, standing for ‘‘purely
epistatic’’, the second disease model (model EPI), three markers
(RL0-75 RL0-153 and RL0-272, Table 2) have been simulated in
order not to display any main effect and associate with the disease
with a purely epistatic penetrance table, with target OR=4.
For each disease model, the following datasets have been
extracted from the population: a) 6 different case-control datasets
with increasing phenocopy level generated with the method
implemented within the software (PM1); b) 6 different case-control
datasets with increasing phenocopy level generated with an
alternative method (PM2) develop in our lab, as described in
materials and methods; c) 6 pedigree datasets with increasing
phenocopy level generated as implemented in genomeSIMLA.
Main effect model
As far as the model ME is concerned, the results show that
strong main effects are not hampered by higher levels of PE,
despite an inflation of the significance (figure 1).
In the case-control dataset with PM1 method, RL0-855 was
highly significant at each phenocopy level until 45%, displayed a
Table 1. The table summarizes the characteristics of the genetic model implemented in the ME model, where one SNP with main
effect has been simulated.
Main effect SNP
dataset target b target OR
main dataset RL0-855 0,80 2,225540928
additional 01 RL0-179 0,80 2,225540928
additional 02 RL0-111 0,80 2,225540928
additional 03 RL0-210 0,80 2,225540928
additional 04 RL0-503 0,80 2,225540928
additional 05 RL0-995 0,80 2,225540928
Interacting SNPs
main effect b target OR
RL0-75 0,000000001 1,000000001
RL0-245 0,000000001 1,000000001
RL0-457 0,000000001 1,000000001
The additional datasets used to pick-up the phenocopies, as implemented in the PM2 method are indicated.
doi:10.1371/journal.pone.0011876.t001
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2log10(p) = 62.54 at 0%PE and a 2log10(p) = 25.84 at 45%. The
analysis of the datasets obtained with the PM2 phenocopy
algorithm produced similar results (see Supplementary Figure
S1): the RL0-855 was significant in the 0% phenocopy dataset
with a 2log10(p) = 67.5, and a 2log10(p) = 31.2 in the 45%
dataset.
A very similar behaviour appears to happen on the pedigrees
dataset, with TDT analysis, even if the overall significance level is
a bit lower (2log10(p) = 40 at 0%PE and 2log10(p) = 8.63, see
Supplementary Figure S2).
Among the other markers where only an interaction was
simulated, only the marker RL0-245 appeared among the top ten
significant at 0%PE (2log10(p) = 11.47) but it was no more on the
top 10 when the phenocopy level reached 10%. The same
happened on the TDT analysis.
Purely epistatic model
When we analyzed the EPI model on the case control dataset,
none of the three markers ranked among the top list of significant
markers. Moreover if we had to correct for multiple testing, none
of the markers would reach a 0.05 level of significance neither at
0% PE level, nor at 45%.
Despite some fluctuations on the data, mainly due to sampling
and data extraction, a positive but no significant trend in the
number of falsely significant markers could be observed according
to the increase of phenocopy error percentage (figure 2). The same
pattern was observable when analyzing the case-control dataset
generated with the PM2 phenocopy method (see Supplementary
Figure S3).
When applying PM2 we observed the appearence of a single
progressively significant marker (RL0-255), which was borderline
for the Hardy-Weinberg equilibrium in the main dataset and
therefore was unbalanced when affected individuals from different
dataset suffering the same simulation phenomenon were added.
This SNP can be considered a false positive, as it was not
simulated in association of the disease in none of the additional
datasets.
A similar behaviour of the markers with a purely epistatic effect
was observable in the pedigree dataset with a TDT analysis: again
none of them ranked as significant (Supplementary Figure S4).
In order to check for the correctness of the model we generated,
we performed a logistic regression on the interaction term between
the three markers we simulated to be associated with a purely
epistatic effect. The p value of the logistic regression was highly
significant both at a 0% PE (p= 7.8*10221) and at a 45% PE
(p= 4.17*1026).
Therefore we decided to analyze the data by using a logic
regression approach. Logic Regression is an adaptive regression
methodology mainly developed to explore high-order interactions
in genomic data and its goal is to find predictors that are Boolean
(logical) combinations of the original predictors. By applying this
methodology the analysis was capable to identify in most cases two
of the three interacting SNPs among the top ranking interactions
(figure 3).
The more the phenocopy error was increasing and the more
these interactions ranked lower, even if in any case at least one of
the three markers (RL0-153) was always present among the top
five.
As a purely epistatic model is a challenge for the analysis in
itself, we adopted a further analysis method, i.e. the multifactor
dimensionality reduction (MDR)[44,52]. MDR analysis was
performed on the EPI model with PM2 phenocopy levels.
Comparably with the logic regression analysis, the MDR
method perfomed with random non exhaustive explorations, was
unable to catch efficiently all the interactions, and this became
more evident with increasing PE levels (Supplementary Table S1).
When testing directly the interacting SNPs, the efficiency and the
OR of the MDR outcome was very close to the modelled one, but
these values progressively decreased the more the PE level
increased: at a 0% PE the predicted OR was 3.80 (compared to
a target OR of the model = 4.0) and at 45% PE the predicted OR
decreased to 2.39 (table 3, and Supplementary Figure S5 and
Supplementary References S1).
Discussion
Investigating the genetic determinants of complex traits
challenges researchers with obstacles yet unresolved completely.
We can argue that the genetic scenario of the most important
complex traits is not explainable in black and white, i.e. only by
the presence of very rare variants yet to be discovered with
sequencing or by the presence of purely epistatic effects. Complex
traits are likely determined by a different contribution of both
causes, with proportions that can differ from a phenotype to
another. In this paper we chose to address this second aspect
which deserves specific attention.
The characterization of the phenotypes is of extreme impor-
tance to this regard, and in our work we focused simulations of
genetic data on the analysis of the effect that phenocopy levels
could have in the capability to understand the genetic determinant
of a disease with different methodologies.
We would like to stress that the concept of ‘‘phenocopy’’ can be
interpreted in several ways, as we pointed out in the introduction,
and that the classical definitions of phenocopies should be largely
revisited in the context of complex traits, where multilocus
genotypes could play a decisive role. Yet this aspect plays a major
role in the discovery of genetic determinants: if to a certain extent
complex traits could be considered by definition phenocopies, and
if purely epistatic interactions play an important role in the missing
heritability (perhaps along undiscovered rare variants), then future
analysis methods have to take into account this scenario and model
not only interactions, but also phenocopy within their statistical
model.
In our simulation we decided to verify the impact of phenocopy
level by testing two methods for the generation of phenocopies: the
PM2 method we developed, specifically produces phenocopies by
introducing affected individuals in which different genetic
Table 2. The table summarizes the SNPs modelled in the
purely epistatic model generation, whose penetrance
function target odds ratio was set to 4.
Epistatic only alternative datasets
dataset interacting SNPs target OR
main dataset RL0-75 RL0-153 RL0-272 4
additional 01 RL0-66 RL0-155 RL0-268 4
additional 02 RL0-123 RL0-79 RL0-337 4
additional 03 RL0-63 RL0-125 RL0-332 4
additional 04 RL0-66 RL0-116 RL0-292 4
additional 05 RL0-63 RL0-120 RL0-329 4
The additional rows indicate the SNPs modelled in the additional datasets used
to pick-up phenocopies according to the PM2 method for phenocopy
generation.
doi:10.1371/journal.pone.0011876.t002
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determinants have been simulated. The PM2 method thus allowed
us to test a scenario where different combinations of loci could
produce the same phenotype.
Our results show that strong main effects are not hampered by
the presence of an increasing amount of phenocopy in the study
sample, despite progressively reducing the significance of the
association, if the study is sufficiently powered.
On the opposite, when purely epistatic effects are simulated, the
capability of identifying the association depends on several
parameters, such as the strength of the interaction between the
polymorphic variants, the penetrance of the polymorphism, the
alleles (minor or major) which produce the combined effect and
their frequency in the population. The influence of these
parameters has been partially discussed in 0% PE datasets in the
literature. In our simulation the critical role of phenocopy
emerges, and the more the PE level increases the more the initial
difficulty in detecting these gene-gene interactions is amplified,
even with methodologies more suitable to the discovery of epistatic
models.
Classical analytical methodologies are very sensible to this error,
and new statistical methods have to be developed, addressing in a
less computing-intensive way SNP-SNP interactions as well as
accounting or adjusting their results on estimates of the phenocopy
error.
Figure 1. Case/control dataset - main effect model. Single point association analysis of the chromosome where a mixed model of marginal
effects and interactions were simulated. The picture shows the impact of the different levels of phenocopy error (PE) on the significance levels. The
point surrounded with a red circle indicates the bin where the SNP with a main effect is located, showing its significance level in the single point
association analysis. In order to simplify the plot, groups of SNPs with similar p values have been grouped into ‘‘bins’’, as performed by the hexbin
package in R. The number of markers in each bin is represented by different shades of blue, as indicated in the legend.
doi:10.1371/journal.pone.0011876.g001
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Since the presence of phenocopy can be a characteristic intrinsic
to the phenotyping of complex traits, we conclude that the neglect
of the possible presence of phenocopies in these scenarios heavily
affects the analysis of their genetic data.
Materials and Methods
Simulations
We performed simulations by using the software genome-
SIMLA[50] which performs the simulation of large-scale genomic
data both in population based case-control samples and in
families. It is a forward-time population simulation algorithm that
allows the user to specify many evolutionary parameters and
control evolutionary processes and allows the user to specify
varying levels of both linkage and LD among and between
markers and disease loci. [48,49,53]. Particular SNPs may be
chosen to represent disease loci according to desired location,
correlation with nearby SNPs, and allele frequency. Up to six loci
may be selected for main effects and all possible 2 and 3-way
interactions. Disease-susceptibility effects of multiple genetic
variables can be modeled using either the SIMLA logistic function
[49,53] or a purely epistatic multi-locus penetrance function [41]
Figure 2. Case/control dataset - purely epistatic model. Single point association analysis of the chromosome where only purely epistatic
effects were simulated. The picture shows the impact of the different levels of phenocopy error (PE) on the significance levels. The points surrounded
with a red circle indicates the bin where the three interacting SNPs are located, showing their significance level in this single point association
analysis. In order to simplify the plot, groups of SNPs with similar p values have been grouped into ‘‘bins’’, as performed by the hexbin package in R.
The number of markers in each bin is represented by different shades of blue, as indicated in the legend.
doi:10.1371/journal.pone.0011876.g002
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found using a genetic algorithm to assign affected status (for
program configuration files see Supplementary Model S1).
Disease models
We generated two different disease models.
In the first one (referred to as ‘‘model ME’’, standing for ‘‘Main
Effect’’) a single SNP (RL0-855, figure 4) was simulated to have a
main effect on disease, with an OR=2.225; at the same time the
disease model included also three other SNPs (RL0-75, RL0-245,
RL0-457) with no main effect and an interaction associated to the
Figure 3. Logic regression on a purely epistatic model. This plot is generated for each dataset of case-control simulations by using a ‘‘logic
regression’’ approaches, and shows the rank of importance of the interactions identified. By applying this methodology the analysis was capable to
identify in most cases two of the three interacting SNPs among the top ranking interactions. The captured associates SNPs are highlighted by arrows.
doi:10.1371/journal.pone.0011876.g003
Table 3. MDR test on purely epistatic model interactions.
Phenocopy level
0% 5% 10% 20% 30% 45%
Testing Accuracy 0.6597 0.6539 0.6492 0.6303 0.6271 0.6098
Testing Sensitivity 0.7061 0.7473 0.7009 0.682 0.5963 0.5655
Testing Specificity 0.6132 0.5621 0.5993 0.5824 0.6547 0.6474
Testing Odds Ratio (CI) 3.8087
(3.1613,4.5887)
3.7956
(3.1397,4.5885)
3.5049
(2.9117,4.2188)
2.9913
(2.4901,3.5934)
2.8012
(2.3359,3.3591)
2.3893
(1.9947,2.862)
This table summarizes the test performed with the multifactor dimensionality reduction method on the RL0-75/RL0-153/RL0-272 interactions at different phenocopy
levels generated with the PM2 method. The target odds ratio for the purely epistatic model of the original dataset was 4: it is evident how at increasing level of
phenocopy, the odds ratio captured by the test for the interacting SNPs progressively decreases.
doi:10.1371/journal.pone.0011876.t003
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affection status. We simulated this model on a single chromosome
with 1.362 markers.
In the second model (referred to as ‘‘model EPI’’, standing for
‘‘purely epistatic’’), we performed a simulation on a smaller
chromosome (401 markers), where no main effect was present and
three SNPs (RL0-75, RL0-153, RL0-272) were affecting disease with
only a purely epistatic disease model, generated by using SIMPEN
[49]. The penetrance table was generated with a target OR=4.
In both simulations the SNP chosen to be associated with the
disease had a MAF.0.30, in order to allow us to simulate the
condition so called ‘‘common variant common disease’’[54,55,56].
Table 1 and Table 2 provide information on the associated
markers and their target OR. Supplementary Figure S6 gives
additional details on the disease model generation.
For each of the two models case-control data and pedigree data
were generated. On each case six different large pooled datasets were
extracted, with an increasing level of phenocopy error (i.e. 0%, 5%,
10%, 20%, 30% and 45%). In order to avoid biases due to data
extraction and fluctuation, each dataset has been obtained by
sampling and then pooling 50 different datasets on each PE level.
The case/control simulation included datasets of 200 cases and
200 controls each, i.e. finally 20.000 individuals each PE level dataset.
Each family simulation included 25 families with 1 affected sib
and 2 unaffected, 25 families with 3 affected and 1 unaffected, 25
families with 2 affected, 2 unaffected sibs and 3 random extra sibs:
the total number of individuals for each dataset of different PE
level was 25.000 samples. Supplementary Figure S7 gives
additional details on the datasets generation.
Generation of the phenocopies
The genomeSIMLA software version used (1.0.7w32), currently
implements a method for generating the phenocopy designed as
follows.
The software generates cases and controls using the penetrance
function and the marker specified by the user. Then, in case-
control datasets, it removes a percentage (user specified) of cases
and replace them with individuals sampled from the control
individuals in the full population and assign them the affected
status. In family datasets, the software determines the total number
of affected to modify as phenocopies, identifies the pedigrees to be
modified and redraw the family according to the new require-
ments. Pedigrees with the required number of affected and
unaffected are selected and then the unaffected phenocopies are
marked as affected, according to the initial design specified by the
user (personal communication).
This method has been referred as ‘‘phenocopy method one’’
(PM1).
In order to verify the correspondence of such phenocopy
generation method with what we defined as ‘‘phenocopy’’ (see
introduction), we also developed another methodology to be
applied on the case-control datasets only. According to this second
algorithm (referred into the article as ‘‘phenocopy method two’’,
PM2), five additional datasets have been generated, with different
markers associated to the affected status. In order to generate the
phenocopy level required, a uniform random sampling of affected
individuals from the five additional datasets have been performed,
and these individuals have been substituted with affected
individuals randomly picked up from the original dataset. This
method generates five datasets with the same phenocopy
percentage as the PM1. Supplementary Figure S8 provides a
more detailed explanation and supplementary Box S1 reports the
R code used to generate these datasets. Table 2 provides
information about the markers associated to the affection status
in the additional datasets and the target OR used.
Statistical analysis
The analysis were conducted using the R software (www.
r-project.org) and PLINK. In particular whole-chromosome case-
control analysis and TDT analysis were performed with PLINK
and visualized with R. The calculation of genetic contrasts and the
logistic regression on single markers, markers’ interaction analysis
with logistic regression where performed according to Clayton as
developed in the ‘‘DGCgenetics’’ package. Interaction analysis by
using a logic regression approach was performed by using the R
package ‘‘logicFS’’ by Schwender, according to the developer’s
specifications.[27]
Figure 4. LD plot from main effect model dataset. Linkage disequilibrium plot of a small portion of the simulated chromosome in the dataset
with main effects. The LD block where the associated SNP (RL0-855) is simulated is visible in the picture. The existence of a block encompassing seven
markers also explains the signal associated with other few SNPs in strong LD with RL0-855.
doi:10.1371/journal.pone.0011876.g004
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The MDR analysis has been conducted by using the MDR
java package (www.epistasis.org)[57] and performing 5.000
random explorations in the model discovery of attributes
ranging from 2 to 4-way interactions, as implemented in the
software.
Supporting Information
Model S1 Model Configuration files.
Found at: doi:10.1371/journal.pone.0011876.s001 (0.01 MB ZIP)
Box S1 R code used to generate the alternative phenocopy
method datasets.
Found at: doi:10.1371/journal.pone.0011876.s002 (0.03 MB
DOC)
References S1 References cited in the Supplementary Infor-
mation.
Found at: doi:10.1371/journal.pone.0011876.s003 (0.03 MB
DOC)
Table S1 The table summarizes the 10 best models for each
phenocopy level identified during the MDR analysis. It has to be
stressed that the MDR analysis has been conducted by performing
5.000 evaluations of possible interactions. An exhaustive analysis
as implemented in the software would be computationally very
intensive, as pointed out by the authors in a recent paper (see
Pattin K. A. et al. [4]). In bold the correct SNPs as modelled in the
purely epistatic penetrance function.
Found at: doi:10.1371/journal.pone.0011876.s004 (0.08 MB
DOC)
Figure S1 For the case-control dataset generated with the main
effect disease model (see SF6), an alternative method of
producing phenocopies has been applied (see SF8). The method
displays the same performance of the internally implemented one,
with the only exception of few markers which progressely fall
outside the equilibrium of Hardy-Weinberg, thus resulting in a
false-positive association (indicated by the arrow). The red circle
indicates the marker associated with the disease in the main
dataset.
Found at: doi:10.1371/journal.pone.0011876.s005 (1.29 MB EPS)
Figure S2 The figure summarizes the significance level for
each marker in the pedigree datasets simulated with a main
effect disease model at each phenocopy level. The red circle
indicates the marker associated with a main effect to the disease
in the model. The PM1 phenocopy generation method was
applied.
Found at: doi:10.1371/journal.pone.0011876.s006 (1.31 MB EPS)
Figure S3 For the case-control dataset generated with the purely
epistatic disease model (see SF6), an alternative method of
producing phenocopies has been applied (see SF8). The method
displays the same performance of the internally implemented one,
with the only exception of one marker which progressively falls
outside the equilibrium of Hardy-Weinberg, thus resulting in a
false-positive association (indicated by the arrow).
Found at: doi:10.1371/journal.pone.0011876.s007 (1.22 MB EPS)
Figure S4 The figure summarizes the significance level of the
markers in pedigree datasets, at each phenocopy level. The red
circles indicate the position of the markers associated in the model,
which is the same in the other plots.
Found at: doi:10.1371/journal.pone.0011876.s008 (1.54 MB EPS)
Figure S5 MDR attribute construction. The figures illustrates
the distribution of cases (left bars) and controls (right bars) when
the three associated SNPs are considered jointly.
Found at: doi:10.1371/journal.pone.0011876.s009 (2.07 MB EPS)
Figure S6 Two disease models have been applied. In the first
model a single SNP displays a main effect (target OR=2.225) and
three additional SNPs do not have a main effect and interact with
each other with a modest effect; this model is implemented as part
of the SIMLA logistic function[1]. In the second model instead,
three SNPs have been simulated as having no main effect, and a
purely espistatic effect on the disease (with a target OR=4); this
model has been implemented in genomeSIMLA and it has been
proposed by Culverhouse [2] and discussed by Moore [2,3].
Found at: doi:10.1371/journal.pone.0011876.s010 (1.07 MB EPS)
Figure S7 For each disease model, two groups of datasets have
been generated: a case-control dataset and a family based dataset. In
order to reduce the fluctuations due to the sampling, in each case 50
different smaller datasets have been independently sampled from the
population and then merged together in order to obtain a large
pooled dataset. The figure explains the process step by step.
Found at: doi:10.1371/journal.pone.0011876.s011 (1.37 MB EPS)
Figure S8 The method has been developed by using the R
software (code provided) in order to perform a random sampling
from five additional datasets where different SNPs have been
associated in the disease model with the affected individuals. A
uniform and random sampling, followed by a random substitution
of the individuals in the original dataset produced different levels
of phenocopies in the sample, thus generating six dataset with
increasing phenocopy percentage. This method ensures the
effective substitution of individuals generated as affected but with
completely different causative markers. The method has been
developed as a further analysis of possible effect generated by the
‘‘phenocopying’’ method implemented in the genomeSIMLA
software.
Found at: doi:10.1371/journal.pone.0011876.s012 (1.67 MB EPS)
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